4月9日,复宏汉霖(02696)发布公告,近日,公司注射用HLX43(靶向PD-L1抗体-新型DNA拓扑异构酶I抑制剂偶联药物)联合汉斯状®(斯鲁利单抗注射液)治疗晚期/转移性实体瘤患者的1b/2期临床研究在中国境内完成首例患者给药。该临床研究分为1b期和2期,第一阶段为开放标签研究,合格的受试者将接受不同剂量的HLX43联合固定剂量的汉斯状®静脉输注给药,每3周一次。第二阶段则是多中心、随机、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.